Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Anthony J Hatswell"'
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0145524 (2015)
BACKGROUND:Evaluating long-term prognosis is important for physicians, patients and payers. This study reports the results of a model developed to predict long-term survival for UK patients receiving second-line ipilimumab. METHODS:MDX010-20 trial da
Externí odkaz:
https://doaj.org/article/683c15a476f94d2cb009ee797f9096c9
Autor:
Anthony J. Hatswell
Publikováno v:
Value in Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9deee922a6ec791f07c2e9fe9fd08d3
https://doi.org/10.1016/j.jval.2023.04.012
https://doi.org/10.1016/j.jval.2023.04.012
Autor:
Mo Yang, Helene Vioix, Emma S. Hook, Anthony J. Hatswell, Rachael L. Batteson, Bruce R. Gaumond, Aurora O’Brate, Sanjay Popat, Paul K. Paik
Publikováno v:
Value in Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cab5224bd6edcbbb2c18f34160d6ed17
https://doi.org/10.1016/j.jval.2023.02.007
https://doi.org/10.1016/j.jval.2023.02.007
Autor:
M Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Anthony J Hatswell, Steve Kanters, Eve H. Limbrick-Oldfield, Sally W Wade, Markqayne D Ray, Jessica Owen, Sattva S Neelapu, John Gribben, John Radford, Sabela Bobillo
Publikováno v:
Palomba, M L, Ghione, P, Patel, A R, Nahas, M, Beygi, S, Hatswell, A J, Kanters, S, Limbrick-Oldfield, E H, Wade, S W, Ray, M D, Owen, J, Neelapu, S S, Gribben, J, Radford, J & Bobillo, S 2023, ' A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma ', Expert Review of Anticancer Therapy, vol. 23, no. 2, pp. 199-206 . https://doi.org/10.1080/14737140.2023.2171994
Scientia
Scientia
Follicular lymphoma; Axicabtagene ciloleucel; Comparative effectiveness Limfoma fol·licular; Axicabtagene ciloleucel; Eficàcia comparativa Linfoma folicular; Axicabtagene ciloleucel; Eficacia comparativa Background In the ZUMA-5 trial (Clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d727090bb434c68e1185c778daaf38
Autor:
Anthony J. Hatswell, Kevin Deighton, Julia Thornton Snider, M. Alan Brookhart, Imi Faghmous, Anik R. Patel
Publikováno v:
Medical decision making : an international journal of the Society for Medical Decision Making. 42(7)
Background When including data from an external control arm to estimate comparative effectiveness, there is a methodological choice of when to set “time zero,” the point at which a patient would be eligible/enrolled in a contemporary study. Where
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450da829388e11e910d0cc9e923da54c
https://pubmed.ncbi.nlm.nih.gov/35514320
https://pubmed.ncbi.nlm.nih.gov/35514320
Autor:
Ioannis Tomazos, Anthony J. Hatswell, Spero Cataland, Peter Chen, Nick Freemantle, Åsa Lommele, Kevin Deighton, Emma Knowles, Neil S. Sheerin, Eric Rondeau
Publikováno v:
Clinical nephrology. 97(5)
Ravulizumab and eculizumab are approved terminal complement inhibitor treatments for atypical hemolytic uremic syndrome (aHUS). Ravulizumab was engineered from eculizumab to have an increased half-life allowing for reduced dosing frequency (8-weekly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4076b37761da81224e515e3974cc6f1b
https://pubmed.ncbi.nlm.nih.gov/34931610
https://pubmed.ncbi.nlm.nih.gov/34931610
Publikováno v:
Applied Health Economics and Health Policy
Background\ud \ud Health state utility values (‘utilities’) are an integral part of health technology assessment. Though traditionally categorised by disease status in oncology (i.e. progression), several recent assessments have adopted values ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55df32d9ee64520d44dfaf720432390a
http://europepmc.org/articles/PMC8060240
http://europepmc.org/articles/PMC8060240
Autor:
Sophie Robinson, G. J. Melendez-Torres, Louise Crathorne, Ash Bullement, Caroline Farmer, Elham Nikram, David Packman, Linda Long, Anthony J. Hatswell
Publikováno v:
PharmacoEconomics. 38:1309-1318
The UK National Institute for Health and Care Excellence (NICE) considered evidence for voretigene neparvovec (VN; Luxturna®) for the treatment of RPE65-mediated inherited retinal dystrophies (IRD) within its highly specialised technology programme.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efef3256d90489a91230054dad95b417
https://doi.org/10.1007/s40273-020-00953-z
https://doi.org/10.1007/s40273-020-00953-z
Autor:
Anthony J. Hatswell, Tanja Podkonjak, Mark J Robinson, Gemma E Shields, Ross Selby, Ash Bullement, Eugene Benson
Publikováno v:
Bullement, A, Podkonjak, T, Robinson, M, Benson, E, Selby, R, Hatswell, A & Shields, G 2020, ' Real-world evidence use in assessments of cancer drugs by NICE ', International Journal of Technology Assessment in Health Care . https://doi.org/10.1017/S0266462320000434
ObjectiveTo establish how real-world evidence (RWE) has been used to inform single technology appraisals (STAs) of cancer drugs conducted by the National Institute for Health and Care Excellence (NICE).MethodsSTAs published by NICE from April 2011 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab1a11728a325da24c426005004fe244
https://doi.org/10.1017/s0266462320000434
https://doi.org/10.1017/s0266462320000434
Publikováno v:
Value in Health. 23:751-759
Objectives To assess the performance of unanchored matching-adjusted indirect comparison (MAIC) by matching on first moments or higher moments in a cross-study comparisons under a variety of conditions. A secondary objective was to gauge the performa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f34051006a176690917091e2e40ded7
https://doi.org/10.1016/j.jval.2020.02.008
https://doi.org/10.1016/j.jval.2020.02.008